Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Snap Inc (SNAP) Price & Performance

Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Snap Inc — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while Snap Inc trades at $5.51 (market cap $9.05B). The key difference: Gilead Sciences, Inc. is far larger — about 18.2× Snap Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Snap Inc pays none. Which is the better fit depends on your goals.

GILDSNAP
Market Cap
$164.99B$9.05B
Sector
HealthMedia
52-Week High
$155.80$9.09
52-Week Low
$110.56$3.93
Enterprise Value
$188.06B$10.61B
Dividend Yield
2.47%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Snap Inc

Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.

Read more on SNAP